Physician profile
Don E Beach
NPI 1366416943
$6,108.62
in general payments reported to CMS, 2019-2025
43 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,182 · 2021: $1,432 · 2022: $898 · 2023: $698 · 2024: $301 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $902.26 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $901.39 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $459.85 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $319.17 | 2019-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $272.38 | 2021-2025 | |
| Abbvie INC. | $266.27 | 2021-2023 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.74 | 2019-2024 | Relistor, Xifaxan |
| Supernus Pharmaceuticals, INC. | $229.47 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $216.69 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Alkermes, INC. | $183.44 | 2022-2023 | Lybalvi |
| Dexcom, INC. | $182.23 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $171.58 | 2019-2023 | |
| Amgen INC. | $169.39 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $134.17 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $130.97 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.